Perrigo Lights Smoking Cessation For Growth With Turnaround Woes 'Fixable'
Executive Summary
As "market leader" in OTC nicotine replacement treatments, Perrigo should "be the one that's doing a lot of innovation," says CEO Murray Kessler. He discussed Perrigo's problems and potential sales drivers as it reported 2018 net sales of $4.7bn, down 4% , and Q4 net sales of $1.2bn, down 7%. Global consumer health product sales for year were flat at $3.9bn and Q4 sales were down 4% at $973m.
You may also be interested in...
Perrigo Strengthens In Europe With Sanofi Skin-Care Brands
Perrigo is investing to grow its reinvigorated International consumer health business by acquiring three OTC skin-care brands from Sanofi.
Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag
Its reported worldwide consumer Q4 net sales increased 12.7%, or 16.4% adjusted for currency exchange rates, product launches and other changes from the prior-year period, to $1.1bn. The s results, though, sent share price plummeting $8.64, more than 14%, to $51.82.
Perrigo Pegs Growth To Initiating OTC Switches, Not Following Brands' NDAs
"A foundation of this business has been," says Perrigo's Americas consumer business chief, Jeffrey Needham, "we are a fast follower. That's been our traditional model. We can't afford to do that going forward." In addition to initiating moving ingredients from Rx to OTC, firm is developing "national better brand" versions of drugs already available OTC.